SCNI
Scinai Immunotherapeutics Ltd.
A Jerusalem-based biopharmaceutical company that develops tiny antibody fragments called NanoAbs, derived from alpacas, to treat inflammatory and skin conditions, and also runs a contract manufacturing service for other biotech startups. It began life in 2003 as BiondVax Pharmaceuticals, focused on a universal flu vaccine, before rebranding as Scinai in 2023. The name is a stylized take on Sinai, the biblical mountain, chosen to mark a fresh start.
ADRUnderlying: SCNICUSIP: 09073Q105HealthcareIL2 holders
American Depositary Shares (ADS), each representing ordinary shares
Total Value
$81.2K
Total Shares
19.5K
Net Share Change
-48.6K
Activity
2 selling
Investor
Value
Shares
Weight
Change
